Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin nasal spray safety in Alzheimer's disease dementia (open-label, single-arm)
jRCTs061200039Completed
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxytocin in Alzheimer's disease (AD). Primary endpoint: Harmful reduction. Started Dec 2020; status: completed.
02
Drugs
oxytocin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCTs061200039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061200039.